Dengue Testing Market Size & Outlook, 2026-2034

Dengue Testing Market Overview

The global dengue testing market size is estimated at USD 639.12 million in 2025 and is projected to reach USD 983.70 million by 2034, growing at a CAGR of 4.95% during the forecast period. The remarkable growth of the market is due to the rising focus on paediatric and maternal health programs, where early dengue detection is prioritized to reduce complications in vulnerable populations.

Key Market Trends & Insights

• North America held a dominant share of the global market, accounting for 33.72% share in 2025.
• The Asia Pacific region is growing at the fastest pace, with a CAGR of 5.12% during the forecast period.
• Based on Product, the ELISA-based tests segment dominated the market in 2025 with a revenue share of 45.64%.
• Based on Type, the POC service segment is expected to register the fastest CAGR growth of 5.89%during the forecast period from 2026 to 2034.
• Based on End User, the clinical labs segment dominated the market in 2025, with a revenue share of 44.16%.
• The U.S. dominates the global dengue testing market, valued at USD 181.74 million in 2024 and reaching USD 189.95 million in 2025.

Graph: U.S. Market Revenue Forecast (2022 – 2034)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 639.12 million
• 2034 Projected Market Size: USD 983.70 million
• CAGR (2025 to 2034): 4.95%
• Dominating Region: North America
• Fastest Growing Region: Asia Pacific

The global market comprises a diverse range of diagnostic technologies aimed at facilitating early detection, accurate differentiation, and efficient management of dengue infections, thereby reducing disease burden and improving clinical outcomes. By product, the market includes ELISA-based tests, Dengue IgG/IgM detection kits, RT-PCR tests, Rapid Diagnostic Tests (RDTs), NS1 antigen detection kits, and lateral flow immunoassays, with Rapid Diagnostic Tests (RDTs) holding a major share owing to their widespread adoption in resource-limited settings for quick and cost-efficient diagnosis. By type, the market is segmented into centralized services and point-of-care (POC) services, where POC services dominate due to their growing use in field settings and primary healthcare centers, enabling faster decision-making and outbreak control. By end user, dengue testing solutions are utilized across hospitals, diagnostic centers, clinical laboratories, and others, with diagnostic centers accounting for a high share as they serve as key hubs for large-scale screening, confirmatory testing, and surveillance programs during dengue outbreaks.

Latest Market Trends

Advancements in Diagnostic Technologies: Shift from Conventional Serology to Multiplex & Sequencing Platforms

A major trend in the global market is the shift from basic antibody or antigen-based serological tests toward more advanced molecular diagnostics, including multiplex PCR, targeted sequencing, and rapid point-of-care assays, enabling faster, more precise, and serotype-specific detection. For example, in December 2024, MGI Tech released its ATOPlex DENV1-4 Targeted Sequencing Package, covering all four dengue virus serotypes. The solution streamlined nucleic acid extraction, library preparation, sequencing, and data analysis, delivering results in about 12 hours for improved surveillance and control. This trend reflected a strong market demand for diagnostics that are faster, more comprehensive, and capable of serotype differentiation.

Mandated Outbreak Surveillance Boosts Dengue Testing Uptake

A key growth trend for the dengue testing market is the global push for mandatory disease surveillance and lab confirmation protocols. Health authorities required faster and more accurate testing, especially in outbreak-prone regions. Recently WHO released updated guidance recommending countries to expand laboratory-based dengue diagnostics, even in remote regions, to improve outbreak response and early case detection. This supported countries in detecting cases earlier, managing outbreaks faster, and preventing hospital overload. It also pushed governments to fund more test kits, upgrade public labs, and adopt point-of-care tools. These actions directly increased the demand for potent dengue testing solutions, accelerating overall market growth and adoption globally.

To get more insights about this report Download Free Sample Report

Dengue Testing Market Drivers

Government Initiatives and Public Health Campaigns

A key driver in the dengue testing market has been the strong focus of governments and public health agencies on launching initiatives and awareness campaigns that improved diagnostic access, strengthened surveillance systems, and educated communities on dengue prevention. For example, in October 2024, the World Health Organization (WHO) launched its Global Strategic Preparedness, Readiness and Response Plan (SPRR) for dengue, which focused on enhancing laboratory diagnostics, expanding disease surveillance, improving vector control, and supporting better clinical management in affected regions. These coordinated actions raised testing adoption worldwide and created an opportunity for sustained market growth through long-term integration of diagnostics into public health systems.

Market Restraint

High Cost of PCR-Based Dengue Testing

A major restraint in the market is the high cost associated with the advanced laboratory equipment and reagents. For example, in August 2025, as per the article published in BioMed Central Ltd, a study from Dhaka, Bangladesh, evaluating the OnSite Dengue Ag Rapid Test, pointed out that PCR based testing, which is considered the gold standard for detecting dengue, is much more expensive and demands specialized equipment and trained staff, making it less accessible in various healthcare settings.

Market Opportunity

Expansion of Diagnostic Infrastructure in Endemic Regions

An opportunity in the global market is the rapid expansion of diagnostic infrastructure in endemic regions to improve disease detection, surveillance, and patient management. For example, in September 2025, India’s Union Health Ministry announced that 869 Sentinel Surveillance Hospitals and 27 Apex Referral Laboratories for provide free dengue testing, with over 5,520 diagnostic kits distributed to states.

This reflected an opportunity for diagnostic companies to collaborate with governments and global health agencies, expand supply chains, and develop high-quality dengue testing solutions tailored for large-scale use in endemic areas.

Regional Analysis

The North America region dominated the market with a revenue share of 33.72% in 2025. The growth is attributed to stronger travel-related dengue screening programs and expanded border health checks, which boosted diagnostic use across airports and clinics.

In the U.S., dengue is classified as a nationally notifiable disease, requiring all suspected cases to be reported and confirmed through laboratory testing under CDC guidelines. This regulation compels hospitals and public health labs to maintain dengue testing capacity, ensuring steady demand for diagnostic assays and strengthening national outbreak preparedness.

Asia Pacific Market Insights

The Asia Pacific region is the fastest-growing region with a CAGR of 5.12% during the forecast timeframe. The growth is attributed to stronger regional policy harmonization and efforts to standardize dengue diagnostics across countries. Collaborative programs encouraged the use of validated assays and cross-border data sharing, improving outbreak response. This created consistent demand for advanced test kits and laboratory systems, boosting adoption not only in endemic nations but also in countries preparing for imported dengue risks.

Japan’s dengue testing market advanced steadily during the forecast period. The growth is attributed to the inclusion of dengue under Japan’s Quarantine Law, which mandated laboratory testing at quarantine stations for international travelers. This legal requirement strengthened diagnostic readiness at airports, ports, and public health labs, ensuring early case detection. Even though dengue is not endemic in Japan, these quarantine measures created consistent demand for potent diagnostics, reinforcing national preparedness and maintaining steady investments in advanced testing capabilities.

Pie Chart: Regional Market Share, 2025

Source: Straits Research

Europe Market Insights

The market is being driven by the integration of advanced vector surveillance programs that monitor Aedes mosquito populations across southern and central regions. Governments and research institutions are increasingly coupling diagnostic data with entomological surveillance and digital mapping tools to predict outbreak risks. This data-driven approach is fostering greater demand for rapid and molecular dengue testing kits that support early detection and public health preparedness.

The dengue testing market in the UK is propelling due to the government’s increasing investment in public health surveillance programs targeting vector-borne diseases. The UK Health Security Agency (UKHSA) has implemented enhanced screening protocols at hospitals and travel clinics to rapidly detect dengue infections, particularly among travellers returning from high-risk regions. This focused approach is boosting the UK dengue testing market size and driving sustained market growth.

Middle East & Africa Market Insights

In the Middle East and Africa, rapid urbanization coupled with rising temperatures is creating favourable conditions for Aedes mosquitoes, leading to higher dengue transmission rates. This trend is driving the demand for advanced dengue diagnostic tests and rapid detection solutions across both urban and peri-urban regions.

South Africa’s dengue testing market is also shaped by the growing emphasis on strengthening public health surveillance and early outbreak detection. With increasing urbanization, certain regions of the country are becoming more susceptible to mosquito proliferation, even though large-scale endemic transmission is rare. This has led government health agencies and private laboratories to invest in enhanced diagnostic infrastructure, including ELISA and RT-PCR testing platforms, to ensure the timely detection of cases. The focus on proactive surveillance and preparedness, rather than solely reactive testing, positions South Africa as a market with a distinct demand for scalable dengue diagnostics.

Latin America Market Insights

Latin American countries are increasingly collaborating on cross-border disease surveillance networks to monitor and control dengue transmission across shared borders. These regional partnerships, supported by organizations like PAHO and local ministries of health, require standardized diagnostic tools to ensure consistent data reporting and case confirmation.

The dengue testing market is expanding due to the government’s efforts to decentralize diagnostic infrastructure beyond major urban centers like Buenos Aires. Provincial laboratories and regional hospitals are being equipped with modern molecular and serological testing systems to manage the rising dengue burden in northern provinces such as Salta and Tucumán. This decentralization enhances local testing capacity, shortens result turnaround times, and increases demand for reliable, locally adaptable diagnostic kits.

Product Insights

The ELISA-based tests segment is dominating the market in 2025 with a revenue share of 45.64%. High segmental shares are due to the fact that they are widely trusted, cost-efficient, and can process large numbers of samples quickly. Supported by WHO and CDC guidelines, ELISA offers detection of both recent and past infections. Its scalability, automation, and easy integration into hospital labs made it the preferred choice worldwide.

The rapid diagnostic tests (RDTs) is anticipated to register the fastest CAGR of 5.12% during the forecast period, owing to the growing demand for point-of-care diagnostics that enable quick and accurate detection of dengue infections, especially in resource-limited and outbreak-prone regions, along with their ease of use and minimal equipment requirements.

Source: Straits Research

Type Insights

The POC service segment is anticipated to grow at a CAGR of 5.89% during 2026-2034. This high growth is because rapid dengue tests at the point of care give results within minutes, supporting doctors to start treatment quickly. These tests are especially useful in rural or outbreak settings where lab access is limited. Their speed, ease of use, and portability made them highly valuable for frontline healthcare, thus boosting segmental growth.

The centralized service dominated the market in 2025, due to the availability of advanced laboratory infrastructure, higher accuracy and reliability of test results, and the ability to handle large volumes of samples for mass screening and surveillance programs during dengue outbreaks.

End User Insights

The clinical labs segment dominated the market in 2025, with a revenue share of 44.16% because they are equipped with advanced diagnostic systems, skilled staff, and high testing capacity, allowing them to handle large patient volumes with accuracy. Their central role in confirming dengue cases, supporting surveillance programs, and ensuring potent results made clinical labs the preferred choice for dengue testing worldwide.

The diagnostic centers is anticipated to register the fastest CAGR of 5.75% during the forecast period, due to the growing demand for decentralized and accessible dengue testing, increasing adoption of rapid diagnostic tests (RDTs) and point-of-care solutions, expansion of outpatient and community healthcare services, and government initiatives promoting early detection and surveillance of dengue outbreaks

Competitive Landscape

The global market is moderately fragmented with multiple players offering diverse testing solutions, including rapid diagnostic kits, molecular assays, and serological tests.

Limay Biosciences: An emerging market player

Limay Biosciences is an emerging player in the dengue testing market, specializing in rapid molecular diagnostic solutions for early detection of all four dengue virus serotypes.

• In March 2025, Limay Biosciences initiated clinical trials for this test at the National University of Rosario’s Center for Public Health Technology. The startup's approach addresses the critical demand for timely and accurate dengue diagnosis, especially in regions with limited access to advanced healthcare infrastructure.

List of key players in Dengue Testing Market

1. Hoffmann-La Roche Ltd
2. Abnova Corporation
3. Abbott
4. Thermo Fisher Scientific Inc.
5. InBios International, Inc.
6. Globetech Media
7. PerkinElmer, Inc.
8. CERTEST BIOTEC
9. DiaSorin S.p.A
10. Quest Diagnostics
11. Grifols Diagnostic Solutions Inc.,
12. Accuquik Test Kits.
13. ACCESS BIO
14. AdvaCare Pharma
15. Jiangsu BioPerfectus Technologies Co., 
16. Prometheus Bio Inc.
17. iCare Medical
18. Hangzhou Lysun Biotechnology Co., Ltd.
19. Neo-Nostics
20. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• December 2024: BIOMERIEUX announced that its BioMérieux Filmarray Tropical Fever Panel received FDA clearance. It is an advanced PCR testing solution enabling rapid and precise identification of pathogens in patients with explained fever, including dengue.
• June 2024: QIAGEN launched QIAcuity digital PCR assays for microbes, including dengue virus serotypes 1–4, enhancing infectious disease research and surveillance.